Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020
(WorldNews Health)

SAN FRANCISCO and SUZHOU, China, Sept. 20, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (`Innovent`) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announce with Eli Lilly and Company (`Lilly`, NYSE: LLY) that the results of the ORIENT-12 study were released in a mini oral presentation at the European Society of Medical Oncology (ESMO) Virtual Congress 2020. ORIENT-12 is the first randomized, double-blind, Phase 3 clinical trial evaluating TYVYT® (sintilimab injection) or placebo in combination with GEMZAR® (gemcitabine) and platinum...